104 related articles for article (PubMed ID: 6210141)
1. Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro.
Covey JM; Zaharko DS
Cancer Treat Rep; 1984 Dec; 68(12):1475-81. PubMed ID: 6210141
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice.
Covey JM; Zaharko DS
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):109-17. PubMed ID: 2578963
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro and in vivo effects of thymidine on L1210 leukemia in mice.
Zaharko DS; Ramonas LM
J Natl Cancer Inst; 1982 May; 68(5):875-80. PubMed ID: 6951095
[TBL] [Abstract][Full Text] [Related]
4. Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.
Grant S; Rauscher F; Margolin J; Cadman E
Cancer Res; 1982 Feb; 42(2):519-24. PubMed ID: 6173114
[TBL] [Abstract][Full Text] [Related]
5. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
[TBL] [Abstract][Full Text] [Related]
6. Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.
Zaharko DS; Covey JM
Cancer Treat Rep; 1984 Oct; 68(10):1255-64. PubMed ID: 6084549
[TBL] [Abstract][Full Text] [Related]
7. Effects of the alpha-D-anomer of 5-aza-2'-deoxycytidine on L1210 mouse leukemic cells in vitro and in vivo.
Veselý J; Pískala A
Cancer Res; 1984 Nov; 44(11):5165-8. PubMed ID: 6207913
[TBL] [Abstract][Full Text] [Related]
8. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Jul; 41(7):2728-37. PubMed ID: 6166368
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro.
Jackson DV; Bender RA
Cancer Res; 1979 Nov; 39(11):4346-9. PubMed ID: 291476
[TBL] [Abstract][Full Text] [Related]
10. Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant.
Zaharko DS; Covey JM; Muneses CC
J Natl Cancer Inst; 1985 Jun; 74(6):1319-24. PubMed ID: 2582176
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
12. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993
[TBL] [Abstract][Full Text] [Related]
13. Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells.
Traganos F; Evenson DP; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Mar; 40(3):671-81. PubMed ID: 6162553
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous infusion of 5-aza-2'-deoxycytidine on survival time of mice with L1210 leukemia.
Momparier RL; Gonzales FA
Cancer Res; 1978 Sep; 38(9):2673-8. PubMed ID: 79443
[No Abstract] [Full Text] [Related]
15. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.
Chlebowski RT; Dietrich M; Akman S; Block JB
Cancer Treat Rep; 1985 May; 69(5):527-32. PubMed ID: 4005875
[TBL] [Abstract][Full Text] [Related]
16. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
17. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
Momparler RL; Veselý J; Momparler LF; Rivard GE
Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
Chabot GG; Momparler RL
Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
[TBL] [Abstract][Full Text] [Related]
19. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
Presant CA; Valeriote F; Vietti TJ
Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
[TBL] [Abstract][Full Text] [Related]
20. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Stegmann AP; Honders MW; Willemze R; Landegent JE
Leukemia; 1995 Jun; 9(6):1032-8. PubMed ID: 7541096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
